✓ Translated by DotMD AI Clinical Council Source: Journal of cellular physiology • Meta-Analysis

Verify Primary Source: NIH PubMed PMID #30145806 ↗

Meta-Analysis: Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials

Original Paper Title: “Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials”

Elena Rostova (AI Quant) Rigor Score

86 / 100

Sample Size (Participants)

Systematic Review

Evidence Classification

Meta-Analysis

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Compared with other regimens, exenatide + metformin reduced fasting plasma glucose (FPG), fasting plasma insulin (FPI), total cholesterol (TC), and homeostasis model assessment insulin resistance index (HOMA-IR) levels, but increased the high-density lipoprotein (HDL) level; vildagliptin + metformin decreased FPI and low-density lipoprote.
Study Design & Sample: Meta-Analysis published in Journal of cellular physiology (Multi-cohort synthesis).
Biostatistical Rigor Score: 86/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of cellular physiology (2019), this meta-analysis evaluating human clinical outcomes investigated: Diabetes mellitus is one of the most prevalent metabolic diseases globally and it is increasing in prevalence. Key clinical takeaway: Compared with other regimens, exenatide + metformin reduced fasting plasma glucose (FPG), fasting plasma insulin (FPI), total cholesterol (TC), and homeostasis model assessment insulin resistance index (HOMA-IR) levels, but increased the high-density lipoprotein (HDL) level; vildagliptin + metformin decreased FPI and low-density lipoprote.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of cellular physiology, 2019-03-15; Meta-Analysis; Rigor 86/100): Compared with other regimens, exenatide + metformin reduced fasting plasma glucose (FPG), fasting plasma insulin (FPI), total cholesterol (TC), and homeostasis model assessment insulin resistance index (HOMA-IR) levels, but increased the high-density lipoprotein (HDL) level; vildagliptin + metformin decreased FPI and low-density lipoprote.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Meta-Analysis). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: metformin-hcl → Rx: metformin-hydrochloride → Rx: glucose-and-sodium-chloride-dextrose-anhydrous-and-sodium-chloride → Rx: exenatide → Condition: blood-glucose → Condition: diabetes →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 30145806: Meta-Analysis: Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials

3 of 3 Free Questions Remaining